RHAPSIDO
Live / Applied — Statement of use — registration review complete (as of 11 Sept 2026)
What this means for you
Not registered yet, but its 30 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98828714
- Mark type
- Stylized text
- Filed
- 30 Oct 2024
- Published for opposition
- 17 Jun 2025
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: anti-inflammatories; dermatological pharmaceutical preparations; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of diseases and disorders of the autoimmune system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for the treatment of cancer and tumors; pharmaceutical preparations for the treatment of allergies
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prior registrations
Prosecution history
- 11 Sept 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 11 Sept 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 29 Aug 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Aug 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 24 Oct 2025 — USE AMENDMENT FILED
- 28 Aug 2026 — SOU EXTENSION 1 GRANTED
- 07 Jul 2026 — SOU EXTENSION 1 FILED
- 10 Feb 2026 — RESPONSE TO ITU OFFICE ACTION ENTERED
- 07 Jul 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 29 Jun 2026 — ITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST
- 18 Jun 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 10 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 24 Oct 2025 — TEAS STATEMENT OF USE RECEIVED
- 12 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED